Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 239
interventional 187
Observational 41
Registry 11

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 100
Drug|placebo 17
Biological|Drug|Procedure 7
Procedure 7
Other 6
Biological 5
Device 4
Drug|Other 4
Drug|Procedure 4
Biological|Drug 3
Radiation 3
Behavioral 2
Behavioral|Drug 2
Biological|Drug|Other|Procedure 2
Biological|Other 2
Diagnostic Test 2
Drug|Other|Procedure|Radiation 2
Drug|Procedure|Radiation 2
Genetic 2
Behavioral|Drug|Procedure 1
Biological|Drug|Other 1
Biological|Drug|Other|Procedure|Radiation 1
Biological|Drug|placebo 1
Biological|placebo 1
Device|Drug|Procedure 1
Device|Procedure 1
Device|Radiation 1
Dietary Supplement|placebo 1
Drug|Genetic|Other|Procedure 1
Other|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 82
France 14
United Kingdom 8
Italy 7
China 3
Japan 3
Spain 3
Switzerland 3
Taiwan 3
Germany 2
Israel 2
Korea, Republic of 2
United States|Brazil|France|Germany|Portugal|Spain|Sweden 2
United States|Italy 2
United States|Spain 2
Argentina|Brazil|France|Germany|Portugal|Sweden 1
Australia 1
Brazil 1
Canada 1
Canada|France|Germany|Greece|Italy|Spain|Turkey|United Kingdom 1
Denmark 1
France|Germany|Italy|Portugal|Spain|Sweden|United Kingdom 1
France|Germany|Portugal|Spain|Sweden|United Kingdom 1
France|Germany|Spain 1
France|Greece|Italy|Netherlands 1
France|Italy 1
France|Portugal|Sweden|United Kingdom 1
Germany|United States|Argentina|Australia|Brazil|Bulgaria|Canada|Cyprus|France|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Portugal|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
Germany|United States|Belgium|Canada|France|Hungary|Ireland|Israel|Italy|Japan|Netherlands|Russian Federation|Spain|Switzerland|Turkey|United Kingdom 1
Guadeloupe|Martinique 1
Iran, Islamic Republic of 1
Mexico|Netherlands|Portugal|Spain|Sweden|United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Cyprus|France|Germany|Greece|Italy|Japan|Korea, Republic of|Malaysia|Taiwan|United Kingdom 1
NA 1
Netherlands 1
Singapore 1
Sweden 1
Turkey|Ukraine|United Kingdom|United States|Belgium|Egypt|Estonia|Finland|France|Georgia|Germany|India|Israel|Italy|Latvia|Lithuania|Netherlands|Peru|Poland|Russian Federation|Spain|Sweden|Tunisia 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Czechia|France|Germany|Hong Kong|Italy|Japan|Netherlands|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Australia|Brazil|Bulgaria|Canada|Cyprus|France|Germany|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Portugal|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Brazil|Czechia|Denmark|France|Italy|Japan|Korea, Republic of|Poland|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Brazil|France|Germany|Italy|New Zealand|Portugal|Spain|United Kingdom 1
United States|Argentina|Brazil|France|Germany|Italy|Portugal|Spain|United Kingdom 1
United States|Argentina|Brazil|France|Germany|Italy|Portugal|Sweden 1
United States|Argentina|Brazil|France|Germany|Portugal|Spain|Sweden|United Kingdom 1
United States|Australia|Austria|France|Germany|Greece|Israel|Italy|Spain|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|China|Denmark|France|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Spain|Sweden|Turkey|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|Czechia|Denmark|Ireland|Israel|Italy|Korea, Republic of|Netherlands|New Zealand|Portugal|Spain|United Kingdom 1
United States|Australia|Brazil|Canada|Czechia|Denmark|France|Germany|Greece|Israel|Italy|Korea, Republic of|Netherlands|Spain|United Kingdom 1
United States|Australia|Germany|Japan|Switzerland 1
United States|Belgium|Brazil|Canada|Czechia|France|Germany|Italy|Japan|Netherlands|Spain|Sweden|United Kingdom 1
United States|Belgium|Canada|China|Greece|Korea, Republic of|Poland|Singapore|Spain|Sweden 1
United States|Belgium|Canada|France|Germany|Italy|Spain|Sweden|United Kingdom 1
United States|Canada 1
United States|Canada|France|Germany|Italy 1
United States|Canada|France|Netherlands|United Kingdom 1
United States|Canada|United Kingdom 1
United States|Czechia|France|Germany|Greece|Israel|Italy|Norway|Poland|Spain|United Kingdom 1
United States|Finland|France|Israel|Italy|Lithuania|Netherlands|Poland|Russian Federation|Spain|Turkey|United Kingdom 1
United States|France|Germany|Italy 1
United States|Germany|Italy 1
United States|Italy|Japan|Sweden|United Kingdom 1
United States|Latvia 1
United States|Portugal|Spain|Sweden 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 102
2 12
3 7
4 8
5 5
6 2
7 4
8 5
9 2
10 7
11 4
12 2
13 2
15 1
17 1
22 1
23 1
24 2
25 1
26 1
31 1
35 1
40 2
46 1
52 1
56 1
61 1
64 1
65 1
66 1
80 1
85 1
86 1
140 1
209 1
345 1

Phase

Phase Study_Count
Phase 2 58
N/A 39
Phase 3 33
Phase 1 29
Phase 1/Phase 2 15
Phase 2/Phase 3 6
Early Phase 1 5
Phase 4 2

Number of Arms

Number_of_Arms Count_of_Studies
1 105
2 55
3 5
4 4
5 2
6 1
7 2
NA 13

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 9.0 5.00000 10.00000 10.0 2.00000 86.0000 4.0000 45.00
1st Qu. 10.0 27.50000 20.00000 23.0 29.25000 122.0000 93.0000 58.25
Median 15.0 60.00000 31.00000 30.0 40.00000 129.0000 177.0000 71.50
Mean 70.8 99.25641 33.31034 36.6 62.81481 131.1667 255.8182 71.50
3rd Qu. 20.0 144.00000 42.00000 46.5 52.25000 145.0000 240.0000 84.75
Max. 300.0 400.00000 85.00000 71.0 422.00000 173.0000 2000.0000 98.00

Trial Group Type

group_type Group_Count
Experimental 193
Active Comparator 31
Placebo Comparator 30
Other 15
NA 13
No Intervention 4
Sham Comparator 3

Intervention Model

intervention_model Study_Count
Single Group Assignment 116
Parallel Assignment 59
NA 5
Crossover Assignment 4
Sequential Assignment 3

Primary Purpose

primary_purpose Study_Count
Treatment 137
Diagnostic 31
Other 9
Health Services Research 3
Supportive Care 3
Prevention 2
Basic Science 1
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 17
NA 5
France 3
Argentina 1
Austria|France|Italy|Romania|Slovenia|Spain 1
Austria|Germany|Switzerland 1
China 1
Germany|India 1
Greece 1
Italy 1
Japan 1
Martinique 1
Spain 1
Sweden 1
Taiwan 1
Turkey 1
United Kingdom 1
United States|Argentina|Belgium|Brazil|Bulgaria|Canada|Cyprus|Denmark|France|Germany|Israel|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Portugal|Romania|Spain|Sweden|Taiwan|Turkey 1
United States|Belgium|Brazil|France|Spain|United Kingdom 1

Sites per Study

Site_count Study_Count
1 27
2 2
3 2
4 2
9 1
10 1
14 1
41 1
58 1
76 1
108 1
207 1

Enrollment Metrics

Measure Observational
Min 1.0000
1st Qu 50.0000
Median 100.0000
Mean 376.6829
3rd Qu 400.0000
Max 5000.0000

Observation Model

observational_model Study_Count
Cohort 20
Case-Only 9
Other 5
NA 3
Case-Control 2
Defined Population, Natural History 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 28
Retrospective 4
Cross-Sectional 3
NA 3
Other 2
Longitudinal, Retrospective 1

Registries

Studies by Country

Country Study_Count
United States 5
China 1
France|Germany|Switzerland 1
Korea, Republic of 1
Spain 1
Sweden 1
Switzerland 1

Sites per Study

Site_count Study_Count
1 10
4 1

Enrollment Metrics

Measure Registries
Min 14.000
1st Qu 37.500
Median 343.000
Mean 1070.182
3rd Qu 1250.000
Max 5000.000

Registry Model

observational_model Study_Count
Cohort 10
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 10
Other 1

Follow-up

target_duration Study_Count
10 Years 4
5 Years 3
1 Year 1
12 Months 1
2 Years 1
21 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04360434 First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy https://ClinicalTrials.gov/show/NCT04360434 Recruiting Neurimmune AG 2021-08-25
NCT04153149 HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy https://ClinicalTrials.gov/show/NCT04153149 Recruiting Alnylam Pharmaceuticals 2024-06-30
NCT03997383 APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) https://ClinicalTrials.gov/show/NCT03997383 Recruiting Alnylam Pharmaceuticals 2021-10-01
NCT03378453 Narcolepsy Protect Against Alzheimer’s Disease? https://ClinicalTrials.gov/show/NCT03378453 Completed University Hospital, Montpellier 2017-11-30
NCT04136184 NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy https://ClinicalTrials.gov/show/NCT04136184 Recruiting Ionis Pharmaceuticals, Inc. 2024-01-31
NCT04136171 CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of AKCEA-TTR-LRx in Participants With Transthyretin‑Mediated Amyloid Cardiomyopathy (ATTR CM) https://ClinicalTrials.gov/show/NCT04136171 Recruiting Ionis Pharmaceuticals, Inc. 2024-01-31
NCT03336580 A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis https://ClinicalTrials.gov/show/NCT03336580 Active, not recruiting Prothena Biosciences Limited 2021-05-30
NCT03322319 Frequency of Cardiac Amyloidosis in the Caribbean’s. (TEAM Amylose) https://ClinicalTrials.gov/show/NCT03322319 Completed University Hospital Center of Martinique 2015-12-02
NCT03315026 Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis https://ClinicalTrials.gov/show/NCT03315026 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-10-31
NCT03311828 Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma https://ClinicalTrials.gov/show/NCT03311828 Recruiting City of Hope Medical Center 2020-07-31
NCT03283917 Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis https://ClinicalTrials.gov/show/NCT03283917 Recruiting M.D. Anderson Cancer Center 2020-10-30
NCT03236792 Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis https://ClinicalTrials.gov/show/NCT03236792 Recruiting Icahn School of Medicine at Mount Sinai 2020-06-30
NCT03232632 Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries. https://ClinicalTrials.gov/show/NCT03232632 Recruiting University Hospital, Toulouse 2019-09-30
NCT03211676 Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer https://ClinicalTrials.gov/show/NCT03211676 Completed Poitiers University Hospital 2018-03-14
NCT03201965 A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT03201965 Active, not recruiting Janssen Research & Development, LLC 2020-02-14
NCT03190577 Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology https://ClinicalTrials.gov/show/NCT03190577 Recruiting Nantes University Hospital 2021-06-30
NCT03129269 Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults https://ClinicalTrials.gov/show/NCT03129269 Recruiting University Hospital, Toulouse 2018-09-30
NCT03119558 PET/MRI Evaluation of Cardiac Amyloid https://ClinicalTrials.gov/show/NCT03119558 Completed Stanford University 2018-08-23
NCT03077620 Sleep Quality and Amyloid-Beta Kinetics https://ClinicalTrials.gov/show/NCT03077620 Recruiting Washington University School of Medicine 2021-06-30
NCT03019029 Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis https://ClinicalTrials.gov/show/NCT03019029 Enrolling by invitation Mayo Clinic 2020-12-31
NCT02994784 Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients https://ClinicalTrials.gov/show/NCT02994784 Recruiting Boston Medical Center 2022-01-31
NCT02959489 Risk Evaluation and Education for Alzheimer’s Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN) https://ClinicalTrials.gov/show/NCT02959489 Recruiting Brigham and Women’s Hospital 2020-05-31
NCT02953808 Phase 1 Study of GSK2315698 in Healthy Japanese Subjects https://ClinicalTrials.gov/show/NCT02953808 Completed GlaxoSmithKline 2016-12-31
NCT02924272 Ixazomib Rollover Study https://ClinicalTrials.gov/show/NCT02924272 Active, not recruiting Takeda 2021-10-01
NCT02911857 An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes https://ClinicalTrials.gov/show/NCT02911857 Completed Novartis 2017-01-27
NCT02909036 Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. https://ClinicalTrials.gov/show/NCT02909036 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-09-30
NCT02841033 Daratumumab for the Treatment of Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT02841033 Active, not recruiting Boston Medical Center 2020-06-30
NCT02816476 Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis https://ClinicalTrials.gov/show/NCT02816476 Active, not recruiting University Hospital, Limoges 2019-12-31
NCT02797847 A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects https://ClinicalTrials.gov/show/NCT02797847 Completed Alnylam Pharmaceuticals 2018-01-12
NCT02791373 Vinorelbine and Gemcitabine in Myeloma https://ClinicalTrials.gov/show/NCT02791373 Completed University Hospital Inselspital, Berne 2017-12-31
NCT02791230 Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy https://ClinicalTrials.gov/show/NCT02791230 Recruiting Pfizer 2026-12-24
NCT02769000 Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer’s https://ClinicalTrials.gov/show/NCT02769000 Active, not recruiting Virginia Commonwealth University 2021-04-30
NCT02775994 Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) https://ClinicalTrials.gov/show/NCT02775994 Recruiting Rabin Medical Center 2020-01-31
NCT02641145 Molecular Imaging of Primary Amyloid Cardiomyopathy https://ClinicalTrials.gov/show/NCT02641145 Recruiting Brigham and Women’s Hospital 2020-03-30
NCT02632786 The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT02632786 Completed Prothena Therapeutics Ltd. 2018-03-31
NCT02595983 The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant https://ClinicalTrials.gov/show/NCT02595983 Completed Alnylam Pharmaceuticals 2017-02-06
NCT01659658 Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT01659658 Active, not recruiting Takeda 2022-06-30
NCT03397810 Effect of Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study https://ClinicalTrials.gov/show/NCT03397810 Recruiting University Hospital, Geneva 2026-02-28
NCT02556502 18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer’s Disease : a Pilot Study https://ClinicalTrials.gov/show/NCT02556502 Completed Central Hospital, Nancy, France 2017-11-30
NCT02510261 The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) https://ClinicalTrials.gov/show/NCT02510261 Active, not recruiting Alnylam Pharmaceuticals 2022-08-31
NCT02425241 Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination https://ClinicalTrials.gov/show/NCT02425241 Completed University College, London 2016-02-29
NCT02338427 Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis https://ClinicalTrials.gov/show/NCT02338427 Completed Centre Hospitalier Departemental Vendee 2018-11-30
NCT02334748 A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies https://ClinicalTrials.gov/show/NCT02334748 Completed Novartis 2018-08-31
NCT02319005 ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) https://ClinicalTrials.gov/show/NCT02319005 Completed Alnylam Pharmaceuticals 2017-03-30
NCT02292186 A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis https://ClinicalTrials.gov/show/NCT02292186 Completed Alnylam Pharmaceuticals 2017-02-22
NCT02260466 Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. https://ClinicalTrials.gov/show/NCT02260466 Recruiting French Cardiology Society 2021-03-31
NCT02245867 Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT02245867 Completed Columbia University 2017-07-23
NCT02207556 Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial https://ClinicalTrials.gov/show/NCT02207556 Active, not recruiting Medical College of Wisconsin 2017-07-31
NCT02191826 Study of SOM0226 in Familial Amyloid Polyneuropathy https://ClinicalTrials.gov/show/NCT02191826 Completed SOM Biotech SL 2015-11-30
NCT02175004 Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) https://ClinicalTrials.gov/show/NCT02175004 Active, not recruiting Ionis Pharmaceuticals, Inc. 2022-06-30
NCT02158052 Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease https://ClinicalTrials.gov/show/NCT02158052 Recruiting Massachusetts General Hospital 2021-02-28
NCT02064153 Studying the Effect of Dialysate Temperature on Toxin Removal and Hypotension https://ClinicalTrials.gov/show/NCT02064153 Completed National University Hospital, Singapore 2014-03-31
NCT02063217 Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction https://ClinicalTrials.gov/show/NCT02063217 Completed Washington University School of Medicine 2016-07-31
NCT02059291 Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers https://ClinicalTrials.gov/show/NCT02059291 Completed Novartis 2017-07-04
NCT01277016 A Trial for Systemic Light-chain (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT01277016 Completed European Myeloma Network 2016-02-29
NCT01273844 Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL) https://ClinicalTrials.gov/show/NCT01273844 Completed Nanjing University School of Medicine 2016-05-12
NCT02055534 Nutritional Counseling in Systemic Immunoglobulin Light-chain Amyloidosis https://ClinicalTrials.gov/show/NCT02055534 Completed IRCCS Policlinico S. Matteo 2013-09-30
NCT02053454 A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers https://ClinicalTrials.gov/show/NCT02053454 Completed Alnylam Pharmaceuticals 2014-03-31
NCT02016365 Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis https://ClinicalTrials.gov/show/NCT02016365 Completed Umeå University 2014-12-31
NCT02015312 A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) https://ClinicalTrials.gov/show/NCT02015312 Completed University Hospital Heidelberg 2017-10-11
NCT03352258 Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer’s Disease https://ClinicalTrials.gov/show/NCT03352258 Recruiting University Hospital, Geneva 2020-12-30
NCT01998503 Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT01998503 Completed Nanjing University School of Medicine 2013-06-30
NCT01994889 Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy https://ClinicalTrials.gov/show/NCT01994889 Completed Pfizer 2018-02-07
NCT01981837 Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis https://ClinicalTrials.gov/show/NCT01981837 Completed Alnylam Pharmaceuticals 2014-10-31
NCT01961921 The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran) https://ClinicalTrials.gov/show/NCT01961921 Completed Alnylam Pharmaceuticals 2016-07-31
NCT01960348 APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis https://ClinicalTrials.gov/show/NCT01960348 Completed Alnylam Pharmaceuticals 2017-08-31
NCT01864018 Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis https://ClinicalTrials.gov/show/NCT01864018 Active, not recruiting Mayo Clinic 2021-01-01
NCT01855360 Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy https://ClinicalTrials.gov/show/NCT01855360 Completed Brigham and Women’s Hospital 2015-05-31
NCT01849783 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT01849783 Active, not recruiting University of Iowa 2020-06-30
NCT01318902 Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis https://ClinicalTrials.gov/show/NCT01318902 Completed Takeda 2018-11-13
NCT01821118 Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy https://ClinicalTrials.gov/show/NCT01821118 Completed Pfizer 2015-09-30
NCT01815086 Radioimmunoimaging of Light Chain (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT01815086 Completed University of Tennessee 2013-07-31
NCT01814839 A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01814839 Completed Alnylam Pharmaceuticals 2015-04-30
NCT03346135 Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma https://ClinicalTrials.gov/show/NCT03346135 Recruiting City of Hope Medical Center 2020-09-05
NCT01789242 A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis https://ClinicalTrials.gov/show/NCT01789242 Completed Criterium, Inc. 2016-12-31
NCT01777243 A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT01777243 Completed GlaxoSmithKline 2015-12-22
NCT01758042 Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders https://ClinicalTrials.gov/show/NCT01758042 Recruiting Massachusetts General Hospital 2019-07-31
NCT01737398 Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy https://ClinicalTrials.gov/show/NCT01737398 Completed Ionis Pharmaceuticals, Inc. 2017-03-03
NCT01728259 First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD https://ClinicalTrials.gov/show/NCT01728259 Active, not recruiting Barbara Ann Karmanos Cancer Institute 2019-12-31
NCT01707264 Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT01707264 Completed Prothena Therapeutics Ltd. 2016-08-09
NCT01683825 Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography https://ClinicalTrials.gov/show/NCT01683825 Recruiting Brigham and Women’s Hospital 2020-06-30
NCT01677286 Safety and Effect of Doxycycline in Patients With Amyloidosis https://ClinicalTrials.gov/show/NCT01677286 Completed Boston University 2015-05-22
NCT01619709 Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage https://ClinicalTrials.gov/show/NCT01619709 Completed University Hospital, Toulouse 2017-06-30
NCT01617967 Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis https://ClinicalTrials.gov/show/NCT01617967 Completed Alnylam Pharmaceuticals 2013-10-31
NCT01570387 A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis https://ClinicalTrials.gov/show/NCT01570387 Active, not recruiting Boston Medical Center 2018-11-30
NCT01559077 Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects https://ClinicalTrials.gov/show/NCT01559077 Completed Alnylam Pharmaceuticals 2012-06-30
NCT01527032 Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT01527032 Completed FDA Office of Orphan Products Development NA
NCT01510613 Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis https://ClinicalTrials.gov/show/NCT01510613 Completed IRCCS Policlinico S. Matteo 2016-12-31
NCT01435655 The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin https://ClinicalTrials.gov/show/NCT01435655 Completed Pfizer 2014-02-28
NCT01409148 Radioimmunoimaging of AL Amyloidosis https://ClinicalTrials.gov/show/NCT01409148 Completed University of Tennessee 2012-03-31
NCT01406314 SAP Depleter Dose Assessment Study in Patients https://ClinicalTrials.gov/show/NCT01406314 Completed GlaxoSmithKline 2012-11-14
NCT01383759 Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis https://ClinicalTrials.gov/show/NCT01383759 Completed Memorial Sloan Kettering Cancer Center 2019-04-30
NCT01323985 SAP Depleter Dose Escalation Study in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01323985 Completed GlaxoSmithKline 2011-06-30
NCT04392960 Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis https://ClinicalTrials.gov/show/NCT04392960 Recruiting IRCCS Policlinico S. Matteo 2023-02-28
NCT04304144 A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT04304144 Recruiting Caelum Biosciences 2020-07-27
NCT04298372 Frontline Lenalidomide for AL Amyloidosis Involving Myocardium https://ClinicalTrials.gov/show/NCT04298372 Recruiting Seoul National University Hospital 2021-03-15
NCT04245098 Carpal Tunnel Syndrome and Amyloidosis https://ClinicalTrials.gov/show/NCT04245098 Recruiting Corporacion Parc Tauli 2022-01-08
NCT04242667 Penn Biobank Return of Research Results Program https://ClinicalTrials.gov/show/NCT04242667 Enrolling by invitation University of Pennsylvania 2020-12-31
NCT04174287 Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer’s Disease https://ClinicalTrials.gov/show/NCT04174287 Recruiting Chang Gung Memorial Hospital 2023-03-27
NCT04146480 The Potential Role of 18F-NaF PET/CT in Diagnosing Cardiac Amyloidosis https://ClinicalTrials.gov/show/NCT04146480 Recruiting Tel-Aviv Sourasky Medical Center 2018-07-31
NCT04131309 A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT04131309 Recruiting European Myeloma Network 2023-01-31
NCT04115956 A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT04115956 Recruiting Oncopeptides AB 2021-11-30
NCT04105634 Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT https://ClinicalTrials.gov/show/NCT04105634 Active, not recruiting University of Pennsylvania 2021-10-01
NCT03996382 Prevalence of Wild Type Transthyretin Cardiac Amyloidosis in Patients Operated for Idiopathic Carpal Tunnel Syndrome https://ClinicalTrials.gov/show/NCT03996382 Recruiting Aarhus University Hospital Skejby 2020-11-01
NCT03969732 Multimodal Biomarkers for Diagnosis and Prognosis in CAA https://ClinicalTrials.gov/show/NCT03969732 Recruiting National Taiwan University Hospital 2022-07-31
NCT03862807 Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant https://ClinicalTrials.gov/show/NCT03862807 Active, not recruiting Alnylam Pharmaceuticals 2021-01-31
NCT03779815 Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography https://ClinicalTrials.gov/show/NCT03779815 Completed Ulsan University Hospital 2019-02-28
NCT03728634 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AKCEA-TTR-LRx in Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis https://ClinicalTrials.gov/show/NCT03728634 Completed Ionis Pharmaceuticals, Inc. 2020-02-20
NCT03720275 Early and Systematic Screening in Chronic Neuropathy https://ClinicalTrials.gov/show/NCT03720275 Recruiting University Hospital, Bordeaux 2020-05-27
NCT03702829 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients https://ClinicalTrials.gov/show/NCT03702829 Recruiting Brigham and Women’s Hospital 2022-01-31
NCT03678259 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT03678259 Recruiting University of Tennessee Graduate School of Medicine 2021-09-01
NCT03610035 A Study of NPT189 in Healthy Subjects https://ClinicalTrials.gov/show/NCT03610035 Completed Proclara Biosciences, Inc. 2019-02-17
NCT04456582 Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Bidimensional Shear Wave Elastography) in Patients With Transthyretin Amyloidosis https://ClinicalTrials.gov/show/NCT04456582 Recruiting University of Sao Paulo General Hospital 2021-01-31
NCT03591757 Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) https://ClinicalTrials.gov/show/NCT03591757 Completed Boston University 2019-04-26
NCT03542656 Application of Amyloid PET in Cerebral Amyloid Angiopathy https://ClinicalTrials.gov/show/NCT03542656 Completed National Taiwan University Hospital 2016-02-17
NCT03499808 S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis https://ClinicalTrials.gov/show/NCT03499808 Active, not recruiting Southwest Oncology Group 2021-10-30
NCT03481972 A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin https://ClinicalTrials.gov/show/NCT03481972 Active, not recruiting IRCCS Policlinico S. Matteo 2021-04-30
NCT03474458 A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy https://ClinicalTrials.gov/show/NCT03474458 Recruiting IRCCS Policlinico S. Matteo 2021-01-31
NCT03464344 Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy. https://ClinicalTrials.gov/show/NCT03464344 Recruiting University Hospital, Toulouse 2022-10-31
NCT03414632 Transthyretin Cardiac Amyloidosis in HFpEF https://ClinicalTrials.gov/show/NCT03414632 Recruiting Mayo Clinic 2020-06-30
NCT01265394 Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects https://ClinicalTrials.gov/show/NCT01265394 Completed GE Healthcare 2011-03-31
NCT01222260 Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis https://ClinicalTrials.gov/show/NCT01222260 Completed Columbia University 2019-03-31
NCT01215747 Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis https://ClinicalTrials.gov/show/NCT01215747 Completed C.T. Development America, Inc. 2016-01-31
NCT01171859 Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis https://ClinicalTrials.gov/show/NCT01171859 Completed IRCCS Policlinico S. Matteo 2015-04-30
NCT01165554 Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels https://ClinicalTrials.gov/show/NCT01165554 Completed GE Healthcare 2011-11-30
NCT01148953 Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis https://ClinicalTrials.gov/show/NCT01148953 Completed Alnylam Pharmaceuticals 2012-01-31
NCT01083316 Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT01083316 Active, not recruiting Boston Medical Center 2013-08-31
NCT01078454 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis https://ClinicalTrials.gov/show/NCT01078454 Completed National Cancer Institute (NCI) 2014-02-28
NCT01072773 Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis https://ClinicalTrials.gov/show/NCT01072773 Completed Mayo Clinic 2011-03-31
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT00952237 Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF https://ClinicalTrials.gov/show/NCT00952237 Completed Dartmouth-Hitchcock Medical Center 2011-04-30
NCT00928304 Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid. https://ClinicalTrials.gov/show/NCT00928304 Completed Life Molecular Imaging SA 2011-01-31
NCT00925002 Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis https://ClinicalTrials.gov/show/NCT00925002 Active, not recruiting Pfizer 2020-05-30
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00890552 A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis https://ClinicalTrials.gov/show/NCT00890552 Completed Stanford University 2012-08-31
NCT00883623 A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT00883623 Completed Heidelberg University 2013-02-28
NCT00857532 Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson’s Disease Patients https://ClinicalTrials.gov/show/NCT00857532 Completed Avid Radiopharmaceuticals 2011-11-30
NCT00857415 Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain https://ClinicalTrials.gov/show/NCT00857415 Completed Avid Radiopharmaceuticals 2010-03-31
NCT03584022 Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial https://ClinicalTrials.gov/show/NCT03584022 Recruiting Mayo Clinic 2020-12-31
NCT02161458 Escitalopram Effects on CSF Amyloid Beta https://ClinicalTrials.gov/show/NCT02161458 Completed University of Pennsylvania 2017-08-31
NCT03252600 Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis https://ClinicalTrials.gov/show/NCT03252600 Recruiting Barbara Ann Karmanos Cancer Institute 2020-09-30
NCT00807872 Radioimmunoimaging of AL Amyloidosis https://ClinicalTrials.gov/show/NCT00807872 Completed University of Tennessee 2012-03-31
NCT03759379 HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) https://ClinicalTrials.gov/show/NCT03759379 Active, not recruiting Alnylam Pharmaceuticals 2021-02-28
NCT03401372 BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients https://ClinicalTrials.gov/show/NCT03401372 Active, not recruiting Peking Union Medical College Hospital 2020-12-20
NCT03618537 Ixazomib Maintenance Study in Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT03618537 Recruiting Memorial Sloan Kettering Cancer Center 2021-08-31
NCT02530255 Telomerase Activator and Retinal Amyloid https://ClinicalTrials.gov/show/NCT02530255 Completed Chippewa Valley Eye Clinic 2018-10-31
NCT03860935 Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy https://ClinicalTrials.gov/show/NCT03860935 Recruiting Eidos Therapeutics 2023-08-31
NCT01138111 Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients https://ClinicalTrials.gov/show/NCT01138111 Completed Life Molecular Imaging SA 2011-12-31
NCT00791492 An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy https://ClinicalTrials.gov/show/NCT00791492 Completed Pfizer 2008-08-31
NCT00790647 Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00790647 Completed Boston Medical Center 2012-12-31
NCT00750282 Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer’s Disease Compared to Healthy Volunteers https://ClinicalTrials.gov/show/NCT00750282 Completed Life Molecular Imaging SA 2010-11-30
NCT00742417 Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid https://ClinicalTrials.gov/show/NCT00742417 Completed Grifols Biologicals, LLC 2011-02-28
NCT00679367 Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00679367 Completed Boston Medical Center 2015-05-31
NCT00651937 Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden https://ClinicalTrials.gov/show/NCT00651937 Completed M.D. Anderson Cancer Center 2016-01-31
NCT00630864 The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis https://ClinicalTrials.gov/show/NCT00630864 Completed Pfizer 2010-01-31
NCT00621400 Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis https://ClinicalTrials.gov/show/NCT00621400 Completed Nantes University Hospital 2009-12-31
NCT00607581 Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT00607581 Completed IRCCS Policlinico S. Matteo 2011-12-31
NCT00564889 Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00564889 Completed Mayo Clinic 2009-02-28
NCT00558896 CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis https://ClinicalTrials.gov/show/NCT00558896 Completed Mayo Clinic 2012-09-30
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT01194791 Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed https://ClinicalTrials.gov/show/NCT01194791 Completed PETHEMA Foundation 2012-09-30
NCT00520767 Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease https://ClinicalTrials.gov/show/NCT00520767 Active, not recruiting Barbara Ann Karmanos Cancer Institute 2010-10-31
NCT00477971 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00477971 Completed Mayo Clinic 2012-07-31
NCT00458822 Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00458822 Completed Memorial Sloan Kettering Cancer Center 2015-03-31
NCT00409175 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis https://ClinicalTrials.gov/show/NCT00409175 Completed Pfizer 2009-05-31
NCT00353392 Q-Switched Nd:YAG in Macular Amyloidosis https://ClinicalTrials.gov/show/NCT00353392 Completed Shahid Beheshti University of Medical Sciences 2006-07-31
NCT00344526 Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis https://ClinicalTrials.gov/show/NCT00344526 Completed University Hospital, Limoges NA
NCT00298766 Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis https://ClinicalTrials.gov/show/NCT00298766 Completed Millennium Pharmaceuticals, Inc. 2009-07-31
NCT00294671 The Effect of Diflunisal on Familial Amyloidosis https://ClinicalTrials.gov/show/NCT00294671 Completed Boston University 2012-12-31
NCT00186407 Autologous Stem Cell Rescue for Primary Amyloidosis https://ClinicalTrials.gov/show/NCT00186407 Completed Stanford University 2008-02-29
NCT00166413 Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00166413 Completed Mayo Clinic 2006-12-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00003353 High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00003353 Completed Eastern Cooperative Oncology Group 2002-12-31
NCT00091260 CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00091260 Completed Boston Medical Center 2012-07-31
NCT00003853 4’-Iodo-4’-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00003853 Completed National Cancer Institute (NCI) 2000-08-31
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00075621 Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis https://ClinicalTrials.gov/show/NCT00075621 Active, not recruiting Boston Medical Center 2005-06-30
NCT00064337 S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00064337 Completed Southwest Oncology Group 2012-05-31
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00007995 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00007995 Completed National Cancer Institute (NCI) 2007-11-30
NCT00002849 S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00002849 Completed Southwest Oncology Group 1998-12-31
NCT00002810 High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis https://ClinicalTrials.gov/show/NCT00002810 Completed Temple University 2006-05-31
NCT00035334 Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis https://ClinicalTrials.gov/show/NCT00035334 Completed Bellus Health Inc NA
NCT00089167 Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT00089167 Completed Memorial Sloan Kettering Cancer Center 2007-12-31
NCT00547365 Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction https://ClinicalTrials.gov/show/NCT00547365 Completed University of Tennessee 2011-07-31
NCT00017680 Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis https://ClinicalTrials.gov/show/NCT00017680 Completed Office of Rare Diseases (ORD) 2004-04-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02021682 CNS and Plasma Amyloid-Beta Kinetics in Alzheimer’s Disease https://ClinicalTrials.gov/show/NCT02021682 Completed Washington University School of Medicine 2017-07-31
NCT03328338 Mitochondrial Function in Transthyretin Amyloidosis https://ClinicalTrials.gov/show/NCT03328338 Recruiting University Hospital Center of Martinique 2019-01-31
NCT03262246 Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid https://ClinicalTrials.gov/show/NCT03262246 Completed Groupe Hospitalier Paris Saint Joseph 2016-12-31
NCT03121118 Return of Amyloid Imaging Results (Result Study) https://ClinicalTrials.gov/show/NCT03121118 Active, not recruiting University of Pittsburgh 2019-09-30
NCT02741999 A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early https://ClinicalTrials.gov/show/NCT02741999 Completed Tufts Medical Center 2020-04-05
NCT02713880 Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP) https://ClinicalTrials.gov/show/NCT02713880 Completed Centogene AG Rostock 2019-12-01
NCT02704065 Recurrent AA Amyloidosis After Renal Transplantation https://ClinicalTrials.gov/show/NCT02704065 Completed Istanbul University 2016-10-31
NCT02587728 Carpal Tunnel/Amyloidosis Blood Sample Study https://ClinicalTrials.gov/show/NCT02587728 Recruiting University of Miami 2020-11-30
NCT02146378 Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan) https://ClinicalTrials.gov/show/NCT02146378 Active, not recruiting Pfizer 2022-04-11
NCT02555969 Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT02555969 Recruiting Tufts Medical Center 2020-08-31
NCT02488720 Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study https://ClinicalTrials.gov/show/NCT02488720 Active, not recruiting University of Southern California 2022-07-31
NCT02485613 Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis https://ClinicalTrials.gov/show/NCT02485613 Completed Nanjing University School of Medicine 2014-12-31
NCT02265718 A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive’s Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers https://ClinicalTrials.gov/show/NCT02265718 Completed Pfizer 2016-05-31
NCT02252653 DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis https://ClinicalTrials.gov/show/NCT02252653 Completed Alnylam Pharmaceuticals 2016-01-31
NCT02111538 Body Composition in Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT02111538 Completed IRCCS Policlinico S. Matteo 2019-04-30
NCT04108091 Vyndaqel Capsules Special Investigation (ATTR-CM) https://ClinicalTrials.gov/show/NCT04108091 Recruiting Pfizer 2024-04-10
NCT01623245 Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy https://ClinicalTrials.gov/show/NCT01623245 Completed French Cardiology Society 2014-12-31
NCT01606280 Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01606280 Completed Mayo Clinic 2013-06-30
NCT01604122 Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers https://ClinicalTrials.gov/show/NCT01604122 Completed Pfizer 2015-07-27
NCT01432587 The Effect of Diflunisal on Familial Transthyretin Amyloidosis https://ClinicalTrials.gov/show/NCT01432587 Completed Umeå University 2014-12-31
NCT01347047 Institutional Registry of Amyloidosis https://ClinicalTrials.gov/show/NCT01347047 Recruiting Hospital Italiano de Buenos Aires 2020-01-31
NCT04201418 A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of hATTR Amyloidosis With a V122I or T60A Mutation https://ClinicalTrials.gov/show/NCT04201418 Recruiting Alnylam Pharmaceuticals 2022-06-30
NCT04068077 Application of High Resolution Optical Coherence Tomography in Skin Disease: Amyloidosis and Differential Diagnosis https://ClinicalTrials.gov/show/NCT04068077 Recruiting Taipei Veterans General Hospital, Taiwan 2019-11-04
NCT04066452 Prevalence of Amyloidosis in Heart Failure (PREVAMIC) https://ClinicalTrials.gov/show/NCT04066452 Recruiting Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 2021-07-01
NCT04027712 Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD https://ClinicalTrials.gov/show/NCT04027712 Active, not recruiting University of Athens 2019-12-31
NCT04006223 The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis https://ClinicalTrials.gov/show/NCT04006223 Recruiting Wuhan Union Hospital, China 2020-12-31
NCT03923920 Screening for Systemic Amyloidosis Via the Ligamentum Flavum https://ClinicalTrials.gov/show/NCT03923920 Recruiting The Cleveland Clinic 2021-04-01
NCT03886155 Cardiac Amyloidosis Screening at Trigger Finger Release https://ClinicalTrials.gov/show/NCT03886155 Recruiting The Cleveland Clinic 2021-04-01
NCT03842163 Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology https://ClinicalTrials.gov/show/NCT03842163 Recruiting Pfizer 2020-07-31
NCT03812172 Screening for Cardiac Amyloidosis Using Nuclear Imaging for Minority Populations https://ClinicalTrials.gov/show/NCT03812172 Recruiting Columbia University 2024-05-31
NCT03626584 PET/MR Imaging In Patients With Cardiac Amyloidosis https://ClinicalTrials.gov/show/NCT03626584 Recruiting University of Edinburgh 2019-11-30
NCT03431896 Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis https://ClinicalTrials.gov/show/NCT03431896 Recruiting The Cleveland Clinic 2024-02-15
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01135849 B-Receptor Signaling in Cardiomyopathy https://ClinicalTrials.gov/show/NCT01135849 Completed Stanford University 2010-10-31
NCT00919139 S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. https://ClinicalTrials.gov/show/NCT00919139 Completed Southwest Oncology Group 2010-11-30
NCT02792790 Carpal Tunnel Syndrome and Amyloid Cardiomyopathy https://ClinicalTrials.gov/show/NCT02792790 Active, not recruiting The Cleveland Clinic 2021-05-31
NCT03373370 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology https://ClinicalTrials.gov/show/NCT03373370 Recruiting Assistance Publique - Hôpitaux de Paris 2020-12-27
NCT03237494 Epidemiological Analysis for the Hereditary Transthytetin-related Amyloidosis (hATTR) https://ClinicalTrials.gov/show/NCT03237494 Recruiting Centogene AG Rostock 2020-12-31
NCT03825224 Evaluation of MyoStrainâ„¢ in Clinical Practice https://ClinicalTrials.gov/show/NCT03825224 Completed University of Kansas Medical Center 2019-11-15
NCT00628745 Transthyretin-Associated Amyloidosis Outcome Survey (THAOS) https://ClinicalTrials.gov/show/NCT00628745 Recruiting Pfizer 2021-06-16
NCT00456040 Characteristics of Patients With Amyloidosis & Heart Failure Being Evaluated for a Heart Transplant https://ClinicalTrials.gov/show/NCT00456040 Completed Massachusetts General Hospital NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02798705 Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis https://ClinicalTrials.gov/show/NCT02798705 Recruiting Samsung Medical Center 2025-04-30
NCT02716103 Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT02716103 Active, not recruiting Boston Medical Center 2020-12-31
NCT02574676 Quality of Life (QOL) Registry for Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT02574676 Completed Prothena Therapeutics Ltd. 2018-07-31
NCT02257905 Allo SCT in Amyloidosis Non-interventional Study https://ClinicalTrials.gov/show/NCT02257905 Completed European Group for Blood and Marrow Transplantation 2015-07-31
NCT01408225 Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource https://ClinicalTrials.gov/show/NCT01408225 Recruiting Ohio State University Comprehensive Cancer Center 2050-03-31
NCT04210791 Autologous Stem Cell Transplantation for Patients With AL Amyloidosis https://ClinicalTrials.gov/show/NCT04210791 Enrolling by invitation Nanjing University School of Medicine 2025-12-31
NCT03984877 Impact of Amyloidosis on TAVI Patients https://ClinicalTrials.gov/show/NCT03984877 Recruiting Hospital Clinico Universitario de Santiago 2021-12-31
NCT03717844 Registry for Adults With Plasma Cell Disorders (PCD’s) https://ClinicalTrials.gov/show/NCT03717844 Recruiting UNC Lineberger Comprehensive Cancer Center 2028-02-29
NCT03527342 Sahlgrenska Cardiomyopathy Project https://ClinicalTrials.gov/show/NCT03527342 Enrolling by invitation Göteborg University 2028-01-31
NCT04061213 ATTR Amyloidosis in Elderly Patients With Aortic Stenosis https://ClinicalTrials.gov/show/NCT04061213 Recruiting University Hospital Inselspital, Berne 2022-12-31
NCT04270058 TEGSEDI Pregnancy Surveillance Program https://ClinicalTrials.gov/show/NCT04270058 Recruiting Akcea Therapeutics 2030-11-15